Loading…
Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for periphera...
Saved in:
| Published in: | Cancer medicine (Malden, MA) MA), 2019-04, Vol.8 (4), p.1467-1473 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3 |
| container_end_page | 1473 |
| container_issue | 4 |
| container_start_page | 1467 |
| container_title | Cancer medicine (Malden, MA) |
| container_volume | 8 |
| creator | Zhang, Zhibo Li, Ye Yan, Xiang Song, Qi Wang, Guoqiang Hu, Yi Jiao, Shunchang Wang, Jinliang |
| description | The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta‐analysis of HR. Pooled estimates of treatment outcomes were calculated by stata 15.1. Six studies with 1136 patients were included in this study. The pooled results of univariate analysis suggested that an elevated pretreatment LDH level was correlated with significant shorter PFS (HR = 1.53, 95% CI 1.27‐1.83, P |
| doi_str_mv | 10.1002/cam4.2024 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cc5f653b56bb4f3cbf5bc30efc344a6a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cc5f653b56bb4f3cbf5bc30efc344a6a</doaj_id><sourcerecordid>2266307774</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3</originalsourceid><addsrcrecordid>eNp1ks9u1DAQhyMEolXpgRdAlrjQw7ZO4thZDkirFX8qFcEBztZkPNn1ksSL7bTaG4_AS_BiPAnObqlaJHyxZX_6Zjz6ZdnznJ_nnBcXCL04L3ghHmXHBRfVTMlSPL53PspOQ9jwtBQvpMqfZkclr0XN5_lx9uuzp-gJYk9DZB1ghEjM0HpnvFvRAIFYDzu29WQsRubGiK4n5loG5hoGJMMGN7DQQ9f9_vETqetYNw4rhtOjZ1uINqkD21dJ9I2Na2b7fhyI4Zrw29bZVNoOa9vY6Hx4zRaspwjJBgN0u2DDs-xJC12g09v9JPv67u2X5YfZ1af3l8vF1QwrPhezqiDDy3peQd7winKhUCg159W8qJGbGo0QJUneqBaNKoiQatVWXNZFI-vWlCfZ5cFrHGz01tse_E47sHp_4fxKg48WO9KIVSursqlk04i2xKatGiw5tVgKARKS683BtR2bngymIXjoHkgfvgx2rVfuWktR17mQSfDqVuDd95FC1L0N03xhIDcGXeTpp6Wq5xP68h9040afhpeoQsqSK6VEos4OFHoXgqf2rpmc6ylLesqSnrKU2Bf3u78j_yYnARcH4MZ2tPu_SS8XH8Ve-QcsTtl4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2266307774</pqid></control><display><type>article</type><title>Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis</title><source>Wiley Online Library Open Access</source><source>PMC (PubMed Central)</source><source>Publicly Available Content (ProQuest)</source><creator>Zhang, Zhibo ; Li, Ye ; Yan, Xiang ; Song, Qi ; Wang, Guoqiang ; Hu, Yi ; Jiao, Shunchang ; Wang, Jinliang</creator><creatorcontrib>Zhang, Zhibo ; Li, Ye ; Yan, Xiang ; Song, Qi ; Wang, Guoqiang ; Hu, Yi ; Jiao, Shunchang ; Wang, Jinliang</creatorcontrib><description>The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta‐analysis of HR. Pooled estimates of treatment outcomes were calculated by stata 15.1. Six studies with 1136 patients were included in this study. The pooled results of univariate analysis suggested that an elevated pretreatment LDH level was correlated with significant shorter PFS (HR = 1.53, 95% CI 1.27‐1.83, P < 0.001) and OS (HR = 2.11, 95% CI 1.43‐3.11, P < 0.001). The association remained significant in the multivariate analysis that elevated pretreatment LDH level was associated with poor PFS (HR = 1.62, 95% CI 1.26‐2.08, P < 0.001) and OS (HR = 2.38, 95% CI 1.37‐4.12, P = 0.002). A high pretreatment LDH level was significantly correlated with shorter PFS and OS. Pretreatment LDH may serve as a predictive biomarker for advanced NSCLC patients treated with ICIs.
Immunotherapy renovates the standard treatment for advanced NSCLC patients, necessitating further investigation into biomarkers to predict its clinical benefits. Compared to genomic characteristics, pretreatment LDH is a readily and cost‐effective index. This meta‐analysis involving six studies with 1136 cases delineates the predicting efficacy of LDH that associates with PFS and OS in NSCLC patients treated with ICIs.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.2024</identifier><identifier>PMID: 30848091</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Bias ; Biomarkers ; Biomarkers, Tumor - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - enzymology ; Clinical Cancer Research ; Dehydrogenases ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immune checkpoint inhibitors ; Immunotherapy ; Immunotherapy - methods ; L-Lactate dehydrogenase ; L-Lactate Dehydrogenase - blood ; Lactic acid ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - enzymology ; Male ; Medical prognosis ; Meta-analysis ; Multivariate analysis ; Neutrophil-to-lymphocyte ratio ; Neutrophils ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Original Research ; Patients ; Peripheral blood ; Peripheral blood biomarker ; Prognosis ; Quality ; Researchers ; Studies ; Survival Analysis ; Treatment Outcome ; Up-Regulation</subject><ispartof>Cancer medicine (Malden, MA), 2019-04, Vol.8 (4), p.1467-1473</ispartof><rights>2019 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3</citedby><cites>FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3</cites><orcidid>0000-0001-6427-3487 ; 0000-0001-9319-5692 ; 0000-0002-8150-5056</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2266307774/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2266307774?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11543,25733,27903,27904,36991,36992,44569,46030,46454,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30848091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Zhibo</creatorcontrib><creatorcontrib>Li, Ye</creatorcontrib><creatorcontrib>Yan, Xiang</creatorcontrib><creatorcontrib>Song, Qi</creatorcontrib><creatorcontrib>Wang, Guoqiang</creatorcontrib><creatorcontrib>Hu, Yi</creatorcontrib><creatorcontrib>Jiao, Shunchang</creatorcontrib><creatorcontrib>Wang, Jinliang</creatorcontrib><title>Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta‐analysis of HR. Pooled estimates of treatment outcomes were calculated by stata 15.1. Six studies with 1136 patients were included in this study. The pooled results of univariate analysis suggested that an elevated pretreatment LDH level was correlated with significant shorter PFS (HR = 1.53, 95% CI 1.27‐1.83, P < 0.001) and OS (HR = 2.11, 95% CI 1.43‐3.11, P < 0.001). The association remained significant in the multivariate analysis that elevated pretreatment LDH level was associated with poor PFS (HR = 1.62, 95% CI 1.26‐2.08, P < 0.001) and OS (HR = 2.38, 95% CI 1.37‐4.12, P = 0.002). A high pretreatment LDH level was significantly correlated with shorter PFS and OS. Pretreatment LDH may serve as a predictive biomarker for advanced NSCLC patients treated with ICIs.
Immunotherapy renovates the standard treatment for advanced NSCLC patients, necessitating further investigation into biomarkers to predict its clinical benefits. Compared to genomic characteristics, pretreatment LDH is a readily and cost‐effective index. This meta‐analysis involving six studies with 1136 cases delineates the predicting efficacy of LDH that associates with PFS and OS in NSCLC patients treated with ICIs.</description><subject>Bias</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - enzymology</subject><subject>Clinical Cancer Research</subject><subject>Dehydrogenases</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>L-Lactate dehydrogenase</subject><subject>L-Lactate Dehydrogenase - blood</subject><subject>Lactic acid</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - enzymology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Multivariate analysis</subject><subject>Neutrophil-to-lymphocyte ratio</subject><subject>Neutrophils</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Original Research</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Peripheral blood biomarker</subject><subject>Prognosis</subject><subject>Quality</subject><subject>Researchers</subject><subject>Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Up-Regulation</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ks9u1DAQhyMEolXpgRdAlrjQw7ZO4thZDkirFX8qFcEBztZkPNn1ksSL7bTaG4_AS_BiPAnObqlaJHyxZX_6Zjz6ZdnznJ_nnBcXCL04L3ghHmXHBRfVTMlSPL53PspOQ9jwtBQvpMqfZkclr0XN5_lx9uuzp-gJYk9DZB1ghEjM0HpnvFvRAIFYDzu29WQsRubGiK4n5loG5hoGJMMGN7DQQ9f9_vETqetYNw4rhtOjZ1uINqkD21dJ9I2Na2b7fhyI4Zrw29bZVNoOa9vY6Hx4zRaspwjJBgN0u2DDs-xJC12g09v9JPv67u2X5YfZ1af3l8vF1QwrPhezqiDDy3peQd7winKhUCg159W8qJGbGo0QJUneqBaNKoiQatVWXNZFI-vWlCfZ5cFrHGz01tse_E47sHp_4fxKg48WO9KIVSursqlk04i2xKatGiw5tVgKARKS683BtR2bngymIXjoHkgfvgx2rVfuWktR17mQSfDqVuDd95FC1L0N03xhIDcGXeTpp6Wq5xP68h9040afhpeoQsqSK6VEos4OFHoXgqf2rpmc6ylLesqSnrKU2Bf3u78j_yYnARcH4MZ2tPu_SS8XH8Ve-QcsTtl4</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Zhang, Zhibo</creator><creator>Li, Ye</creator><creator>Yan, Xiang</creator><creator>Song, Qi</creator><creator>Wang, Guoqiang</creator><creator>Hu, Yi</creator><creator>Jiao, Shunchang</creator><creator>Wang, Jinliang</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6427-3487</orcidid><orcidid>https://orcid.org/0000-0001-9319-5692</orcidid><orcidid>https://orcid.org/0000-0002-8150-5056</orcidid></search><sort><creationdate>201904</creationdate><title>Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis</title><author>Zhang, Zhibo ; Li, Ye ; Yan, Xiang ; Song, Qi ; Wang, Guoqiang ; Hu, Yi ; Jiao, Shunchang ; Wang, Jinliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bias</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - enzymology</topic><topic>Clinical Cancer Research</topic><topic>Dehydrogenases</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>L-Lactate dehydrogenase</topic><topic>L-Lactate Dehydrogenase - blood</topic><topic>Lactic acid</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - enzymology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Multivariate analysis</topic><topic>Neutrophil-to-lymphocyte ratio</topic><topic>Neutrophils</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Original Research</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Peripheral blood biomarker</topic><topic>Prognosis</topic><topic>Quality</topic><topic>Researchers</topic><topic>Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Zhibo</creatorcontrib><creatorcontrib>Li, Ye</creatorcontrib><creatorcontrib>Yan, Xiang</creatorcontrib><creatorcontrib>Song, Qi</creatorcontrib><creatorcontrib>Wang, Guoqiang</creatorcontrib><creatorcontrib>Hu, Yi</creatorcontrib><creatorcontrib>Jiao, Shunchang</creatorcontrib><creatorcontrib>Wang, Jinliang</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Zhibo</au><au>Li, Ye</au><au>Yan, Xiang</au><au>Song, Qi</au><au>Wang, Guoqiang</au><au>Hu, Yi</au><au>Jiao, Shunchang</au><au>Wang, Jinliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2019-04</date><risdate>2019</risdate><volume>8</volume><issue>4</issue><spage>1467</spage><epage>1473</epage><pages>1467-1473</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta‐analysis of HR. Pooled estimates of treatment outcomes were calculated by stata 15.1. Six studies with 1136 patients were included in this study. The pooled results of univariate analysis suggested that an elevated pretreatment LDH level was correlated with significant shorter PFS (HR = 1.53, 95% CI 1.27‐1.83, P < 0.001) and OS (HR = 2.11, 95% CI 1.43‐3.11, P < 0.001). The association remained significant in the multivariate analysis that elevated pretreatment LDH level was associated with poor PFS (HR = 1.62, 95% CI 1.26‐2.08, P < 0.001) and OS (HR = 2.38, 95% CI 1.37‐4.12, P = 0.002). A high pretreatment LDH level was significantly correlated with shorter PFS and OS. Pretreatment LDH may serve as a predictive biomarker for advanced NSCLC patients treated with ICIs.
Immunotherapy renovates the standard treatment for advanced NSCLC patients, necessitating further investigation into biomarkers to predict its clinical benefits. Compared to genomic characteristics, pretreatment LDH is a readily and cost‐effective index. This meta‐analysis involving six studies with 1136 cases delineates the predicting efficacy of LDH that associates with PFS and OS in NSCLC patients treated with ICIs.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>30848091</pmid><doi>10.1002/cam4.2024</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-6427-3487</orcidid><orcidid>https://orcid.org/0000-0001-9319-5692</orcidid><orcidid>https://orcid.org/0000-0002-8150-5056</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-7634 |
| ispartof | Cancer medicine (Malden, MA), 2019-04, Vol.8 (4), p.1467-1473 |
| issn | 2045-7634 2045-7634 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_cc5f653b56bb4f3cbf5bc30efc344a6a |
| source | Wiley Online Library Open Access; PMC (PubMed Central); Publicly Available Content (ProQuest) |
| subjects | Bias Biomarkers Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Clinical Cancer Research Dehydrogenases Female Gene Expression Regulation, Neoplastic Humans Immune checkpoint inhibitors Immunotherapy Immunotherapy - methods L-Lactate dehydrogenase L-Lactate Dehydrogenase - blood Lactic acid Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Male Medical prognosis Meta-analysis Multivariate analysis Neutrophil-to-lymphocyte ratio Neutrophils Non-small cell lung cancer Non-small cell lung carcinoma Original Research Patients Peripheral blood Peripheral blood biomarker Prognosis Quality Researchers Studies Survival Analysis Treatment Outcome Up-Regulation |
| title | Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A45%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20lactate%20dehydrogenase%20may%20predict%20outcome%20of%20advanced%20non%20small%E2%80%90cell%20lung%20cancer%20patients%20treated%20with%20immune%20checkpoint%20inhibitors:%20A%20meta%E2%80%90analysis&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Zhang,%20Zhibo&rft.date=2019-04&rft.volume=8&rft.issue=4&rft.spage=1467&rft.epage=1473&rft.pages=1467-1473&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.2024&rft_dat=%3Cproquest_doaj_%3E2266307774%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5094-52ed03895a1b05e147c477905928c0d8cd443e60b7fcd72eece87f50682b68fd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2266307774&rft_id=info:pmid/30848091&rfr_iscdi=true |